The estimated Net Worth of Shelly D Guyer is at least $6.58 Milion dollars as of 14 June 2021. Ms. Guyer owns over 9,910 units of Invitae Corp stock worth over $4,840 and over the last 11 years she sold NVTA stock worth over $3,662,378. In addition, she makes $2,913,200 as Chief Financial Officer at Invitae Corp.
Sign up
Ms. Guyer NVTA stock SEC Form 4 insiders trading
Shelly has made over 18 trades of the Invitae Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 9,910 units of NVTA stock worth $313,453 on 14 June 2021.
The largest trade she's ever made was selling 24,447 units of Invitae Corp stock on 19 August 2019 worth over $620,465. On average, Shelly trades about 4,366 units every 82 days since 2014. As of 14 June 2021 she still owns at least 241,975 units of Invitae Corp stock.
You can see the complete history of Ms. Guyer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Shelly Guyer biography
Shelly D. Guyer serves as Chief Financial Officer of the Company. Ms. Guyer served as Chief Financial Officer of Veracyte, Inc., a genomic diagnostics company, from April 2013 to December 2016 and served as Veracyte’s Secretary from April 2013 to March 2014. Previously, she served as Chief Financial Officer and Executive Vice President of Finance and Administration of iRhythm Technologies, Inc., a digital healthcare company, from April 2008 to December 2012. From March 2006 to August 2007, Ms. Guyer served as Vice President of Business Development and Investor Relations of Nuvelo, Inc., a biopharmaceutical company. Prior to joining Nuvelo, Ms. Guyer worked at J.P. Morgan Securities and its predecessor companies for over 17 years, serving in a variety of roles including in healthcare investment banking. Ms. Guyer currently serves as a director of NGM Biopharmaceuticals, Inc., a publicly held biopharmaceutical company. Ms. Guyer holds an A.B. in Politics from Princeton University and an M.B.A. from the Haas School of Business at the University of California Berkeley.
What is the salary of Shelly Guyer?
As the Chief Financial Officer of Invitae Corp, the total compensation of Shelly Guyer at Invitae Corp is $2,913,200. There are 1 executives at Invitae Corp getting paid more, with Sean George having the highest compensation of $5,319,510.
How old is Shelly Guyer?
Shelly Guyer is 59, she's been the Chief Financial Officer of Invitae Corp since 2017. There are 6 older and 12 younger executives at Invitae Corp. The oldest executive at Invitae Corp is Dr. Robert L. Nussbaum, 71, who is the Chief Medical Officer.
What's Shelly Guyer's mailing address?
Shelly's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Invitae Corp
Over the last 10 years, insiders at Invitae Corp have traded over $68,349,838 worth of Invitae Corp stock and bought 2,982,686 units worth $18,086,236 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... a James E Deerfield Mgmt L.P..... On average, Invitae Corp executives and independent directors trade stock every 14 days with the average trade being worth of $540. The most recent stock trade was executed by Robert L Nussbaum on 13 June 2023, trading 7,086 units of NVTA stock currently worth $9,779.
What does Invitae Corp do?
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
What does Invitae Corp's logo look like?
Complete history of Ms. Guyer stock trades at Veracyte Inc, Invitae Corp a Ngm Biopharmaceuticals Inc
Invitae Corp executives and stock owners
Invitae Corp executives and other stock owners filed with the SEC include:
-
Sean George,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Shelly Guyer,
Chief Financial Officer -
Katherine Stueland,
Chief Commercial Officer -
Robert Nussbaum,
Chief Medical Officer -
Shelly D. Guyer,
Chief Financial Officer -
Dr. Sean Emerson George Ph.D.,
Co-Founder, Pres, CEO & Director -
Lee Bendekgey,
Chief Policy Officer -
Geoffrey Crouse,
Independent Director -
Eric Aguiar,
Independent Director -
Christine Gorjanc,
Lead Independent Director -
Chitra Nayak,
Independent Director -
Jason Myers,
Director -
Kimber Lockhart,
Director -
Karthik Suri,
Chief Digital Officer -
Thomas Brida,
General Counsel, Secretary -
Robert Werner,
Chief Accounting Officer -
Kenneth Knight,
Chief Operating Officer -
Glenn Medalle,
Head of Talent -
Dr. Robert L. Nussbaum,
Chief Medical Officer -
Robert F. Werner,
Chief Accounting Officer & Principal Accounting Officer -
Desarie French,
Chief Talent Officer -
Laura D'Angelo,
Head of Investor Relations -
Yafei Wen,
Chief Financial Officer -
Layton Wedgeworth,
Chief Technology Officer -
Kenneth D. Knight,
Chief Operating Officer -
Michele Cargill Ph.D.,
Co-Founder, Key Projects & Advisor to the CEO -
Alex Furman,
Co-Founder, Culture Tsar & Head of People Analytics -
Bros. Advisors Lp Baker Bro...,
-
Bros. Advisors Lpbaker Feli...,
-
Mc Nerney & Partners Ii L.P...,
-
Lisa Alderson,
Senior VP, Marketing -
William H Osborne,
Director -
Patty Dumond,
-
Eric Thomas, Mc Nerney & Pa...,
-
James E Deerfield Mgmt L.P....,
-
E Lee Bendekgey,
Chief Operating Officer -
Randal W. Scott,
Director -
Yafei Wen,
Chief Financial Officer -
Robert M. Guigley,
Chief Commercial Officer -
David Sholehvar,
Chief Operating Officer -
Ana J. Schrank,
Chief Financial Officer